New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and management of lupus nephritis (LN), which prioritize the urgent need to use efficacious treatments to avoid nephron loss and preserve kidney function. The guidelines call for a triple immunosuppression treatment regimen for LN, with first line use of advanced therapies like LUPKYNIS for three to five years. Importantly, the guidelin

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE), and reinforce the clinical importance of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adults with active LN. "The data we are presenting at ACR highlight the pivotal role the rheumatology community must play in diagnosing and managing lupus nephritis. Rheu

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM GMT/7:00 AM EST. This session will not include a webcast. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry. He previously served as a director of Ardea Biosciences, Inc., Adamis Pharmaceuticals Corporation, Decipher Biosciences, Inc., La Jolla Pharmaceutical Company, Odonate Therapeutics, Inc. and Mirati Therapeutics, Inc. He currently serves as a director of Heron Therapeutics, Inc. His biography can be found here. The Company also announced that Dr. Robert

Achieved $67.8 million in total net revenue and $55.5 million in net product revenue for the third quarter of 2024, representing year-over-year growth of 24% and 36%, respectively Generated $17.0 million in cash flow from operations in the third quarter and had cash, cash equivalents, restricted cash, and investments of $348.7 million as of September 30, 2024 Anticipates a one-time restructuring charge in the fourth quarter of 2024 of $15 to $19 million and estimates post-restructuring annualized cash-based operating expense savings of more than $40 million Reiterates 2024 net product revenue guidance range of $210 to $220 million for fiscal year 2024 Webcast and conference call to

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024. Aurinia's management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. Webcast & Conference Call Details The link to the audio webcast is available here. To join the conference call, please dial (800) 715-9871 / +1 (646) 307-1963. Conference ID: 6251719 or company name required for entry. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a fully

-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology (ASN) Kidney Week 2024 taking place in San Diego, CA October 23-27. These data reinforce the clinical importance of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adults with active lupus nephritis (LN). "The data featured at ASN elucidate the critical role LUPKYNIS plays in advancing the treatment of lupus nephritis, especially in populations disproportionately impacted by the disease. We're particularly excited about moving our ENLIGHT-LN™ registry fo

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat lupus nephritis (LN). The Company's collaboration partner, Otsuka Pharmaceutical Co., Ltd., filed the new drug application (NDA) with Japanese regulatory authorities in November 2023. The approval is based on data from the AURORA Clinical Program, which included a 12-month, Phase 3, double-blind, randomized-controlled study, as well as a two-year extension study, assessing the efficacy and safety of voclosporin with MMF and lo

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's management team will attend the 2024 Cantor Fitzgerald Global Healthcare Conference in New York City, September 17-19, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 17th, at 3:05 PM EDT. A live webcast of the session will be available on the Investor section of Aurinia's website, which can be found here. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical n

Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity

Achieved $67.8 million in total net revenue and $55.5 million in net product revenue for the third quarter of 2024, representing year-over-year growth of 24% and 36%, respectively Generated $17.0 million in cash flow from operations in the third quarter and had cash, cash equivalents, restricted cash, and investments of $348.7 million as of September 30, 2024 Anticipates a one-time restructuring charge in the fourth quarter of 2024 of $15 to $19 million and estimates post-restructuring annualized cash-based operating expense savings of more than $40 million Reiterates 2024 net product revenue guidance range of $210 to $220 million for fiscal year 2024 Webcast and conference call to

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024. Aurinia's management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. Webcast & Conference Call Details The link to the audio webcast is available here. To join the conference call, please dial (800) 715-9871 / +1 (646) 307-1963. Conference ID: 6251719 or company name required for entry. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a fully

Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter and had cash, cash equivalents, restricted cash and investments of $330.7 million as of June 30, 2024 Company announces development strategy for AUR200, its potential next generation pipeline asset for autoimmune diseases targeting BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand) Company narrows 2024 net product revenue guidance range to $210 to $220 million Confere

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (866) 682-6100 or (862) 298-0702 (toll-free U.S. & Canada). The audio webcast can also be accessed here. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to pe

Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and extending the trend of consistent growth in LUPKYNIS® (voclosporin) sales Rapidly completed restructuring while maintaining focus on commercial execution Ahead of prior projections, Company expects to be cash flow positive, excluding share repurchases, in second quarter 2024, with estimated cost savings of $50 to $55 million annually Company reiterates 2024 net product revenue guidance of $200 to $220 million Conference call to be hosted today at 8:30 a.m. ET Aurinia Pharmaceutical

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the first quarter of 2024 on Thursday, May 2, 2024, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada). The audio webcast can also be accessed here. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people liv

Total net revenue was $45.1 million and $175.5 million, and net product revenue was $42.3 million and $158.5 million, for the fourth quarter and full year 2023, respectively $350.7 million of cash, cash equivalents, restricted cash and investments as of December 31, 2023 Reaffirms 2024 net product revenue guidance of $200 - $220 million Announces conclusion of strategic review and details operational changes that are expected to drive savings of approximately $50 - $55 million annually Initiates a share repurchase program of up to $150 million (the maximum amount of which is subject to receipt of regulatory approval in Canada) Conference call to be hosted today at 8:30 a.m.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release 2023 fourth quarter and full year financial and operational results on Thursday, February 15, 2024, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia's website. About Aurinia Au

WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE, OTCQB:KNBIF) (the "Company", "Kane" or "Kane Biotech") announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the "Meeting") to consider the election of Dr. Robert Huizinga as an additional director of the Company. The information circular and other materials with respect to the Meeting will be filed on SEDAR+ by the Company in due course. Dr. Huizinga is currently the principal of Reformation Consulting Services. He was formerly the Executive Vice-President of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) and led the clinical development of voclosporin which had

Net product revenue of $40.8 million for the third quarter of 2023; an increase of 60% over the prior year third quarter Total net revenue of $130.4 million for the nine months ended September 30, 2023, an increase of 24% over prior year Achieved European pricing and reimbursement milestone triggering $10 million payment from Otsuka Pharmaceutical Co. Ltd. Narrowing 2023 net product revenue guidance range to $155 - $160 million from net product sales of LUPKYNIS® (voclosporin) Conference call to be hosted today at 8:30 a.m. ET Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 202

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry. He previously served as a director of Ardea Biosciences, Inc., Adamis Pharmaceuticals Corporation, Decipher Biosciences, Inc., La Jolla Pharmaceutical Company, Odonate Therapeutics, Inc. and Mirati Therapeutics, Inc. He currently serves as a director of Heron Therapeutics, Inc. His biography can be found here. The Company also announced that Dr. Robert

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four directors, while elected under applicable corporate law, who received less than majority support are Peter Greenleaf, Director, President and CEO; Daniel G. Billen, Ph.D., Director, Chair of the Board, Chair of the Compensation Committee, and Member of the Audit Committee; R. Hector MacKay-Dunn, J.D., K.C., Director, Chair of the Governance & Nomination Committee and Member of the Compensation Committ

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced that its Board of Directors ("the Board") has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, "MKT Capital") submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board. In connection with Dr. Foster's appointment, MKT Capital has entered into a cooperation agreement with Aurinia. A complete copy of the cooperation agreement will be available on our profiles on EDGAR and SEDAR. "We are appreciative of MKT's constructive collaboration efforts. Dr. Foster brings talents which can help strengthen the Board even further

Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia's Board of Directors August 18, 2023 Dr. Daniel G. Billen appointed Chair of the Board of Directors Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced that its Board of Directors has appointed two new directors. Dr. Karen Smith and Jeffrey A. Bailey joined the board of directors of the Company effective August 18, 2023, bringing with them decades of combined leadership experience in the pharmaceutical and biotech industry. After conducting a broad search for new directors from a diverse and qualified pool of candidates, Dr. Smith and Mr. Bailey rose to the top because their distinguished careers pr

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced voting results for its annual general meeting (the "Meeting") of shareholders held on May 17, 2023. Shareholders re-elected six of eight incumbent directors to the Board of Directors (the "Board"). Two directors, George Milne and Joseph ("Jay") Hagan, while elected under applicable corporate law, received less than majority support and have submitted their resignations for consideration by the Board, pursuant to the Company's Majority Voting Policy. In accordance with the policy, the Board intends to act expeditiously in respect to the submitted resignations to ensure an orderly transition. In additi

 Leading independent proxy advisor also recommends shareholders vote for say-on-pay, equity incentive plan amendment, and appointment of auditors Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia's continued momentum Shareholders with questions or who require assistance voting their shares should contact Laurel Hill Advisory Group toll free within North America at 1-877-452-7184 (1-416-304-0211 outside North America), or by email at [email protected]. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced that Glass Lewis & Co. ("Glass Lewis"), a leading independent proxy advisor, has recomme

Volker Knappertz, MD, as Executive Vice President, Research and Development, to lead the consolidated R&D function and to further enhance and advance the Aurinia pipeline Scott Habig, as Chief Commercial Officer, to lead and enhance Aurinia's commercial capabilities, replacing Max Colao, who led the formation of the commercial organization and the launch of Aurinia's first FDA-approved product LUPKYNIS® DeDe Sheel, as Vice President of Investor Relations (IR), to manage all aspects of investor relations programs to support company growth Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the co

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company's Board of Directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corporate and Business Development of BioMarin Pharmaceutical Inc. ("BioMarin"), a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare disorders. At BioMarin, Dr. Balakrishnan leads initiatives on corporate strategy, mergers and acquisitions, partnering and licensing. This press release features multimedia. View the full release here: https://www.businesswire.c

- Reuters

The Company recommends that shareholders review the recent report from proxy advisor Glass Lewis, which recommends shareholders vote for the re-election to the Board of Directors of all nine incumbent directors.

The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), in combination with MMF and steroids, for the treatment of adult patients with active lupus nephritis (LN), as shown in the AURORA Clinical Program.

Outlines Concerns Regarding the Company's Current Strategy and Board Composition and Offers Superior Paths to Improving Performance and Market PenetrationLucien Selce, who owns approximately 2.2% of the outstanding shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company"), today issued the following letter to Aurinia shareholders:May 7, 2024Fellow Shareholders,As a shareholder of Aurinia since 2020, I have grown increasingly worried about the Company's trajectory and am disappointed in the Board of Directors' (the "Board") actions. This is why I now feel dutybound to publicly share my concerns and ideas for improving the Company.In recent years, Aurinia has faced chal

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.14) by 50 percent. The company reported quarterly sales of $50.300 million which beat the analyst consensus estimate of $47.453 million by 6.00 percent. This is a 46.18 percent increase over sales of $34.409 million the same period last year.